News

\r\n The old traders’ adage “better to travel than arrive” has been true in 2017. Last year wa...
\r\n President Donald Trump signed on 28 March 2017 an executive order to unravel former President B...
\r\n According to some scientists, the fingerprint of human-caused climate change has been found on ...
\r\n Australia’s federal government has announced it will ratify and implement the OPCAT Treaty, O...
\r\n Nurses and teachers are among those bearing the brunt of a debt crisis rooted in the mistaken b...

Follow us

Articles

CHINESE CORRUPTION IN HEALTHCARE SECTOR: THE CRACKDOWN ON PHARMACEUTICAL COMPANIES IS LIKELY TO BE INTENSIFIED

A unit of China's anti-trust regulator has visited the Swiss Roche Holding AG,the second Swiss pharmaceutical firm in the country to attract the Chinese government scrutiny. Last week Chinese authorities charged executives at British drugmaker GlaxoSmithKline (GSK) over bribery and corruption, and legal and industry sources have said the crackdown on the pharmaceutical sector is likely to be intensified.

In 2013 the National Development and Reform Commission (NDRC), China's top economic planning body that regulates prices, initiated investigations of 60 foreign and local pharmaceutical firms, such as Novartis, Britain's AstraZeneca, US drugmaker Eli Lilly, France's Sanofi, German drugmaker Bayer, Danish firms Novo Nordisk and H. Lundbeck, and Belgian firm UCB.

Corruption charges against GSK's former China boss, Mark Reilly, represent an alarming sign to multi-nationals that are keen to set up shops in the country. Corruption is rife in China's healthcare sector, driven by high targets for sales staff and low salaries for doctors.

Foreign and local pharmaceutical companies compete intensely with each other in an effort to enlarge their market share in China's booming pharmaceutical sector.
China has become a magnet for global drugmakers and medical devices markets, it is a key growth market for Roche, which has sold its drugs in the country rising by 21 percent last year
.

Drugmakers have poured resources into China over the past decade as rising incomes have made health care more affordable for many. At the same time, the government has spent $180 billion since 2009 to advance its goal of providing basic care for more than 90 percent of its citizens. President Xi has made affordable health care a key part of the Communist Party’s agenda.

 

The gLAWcal Team

Thursday, May 22, 2014

(Source: International Business Times)

This news has been realized by gLAWcal—Global Law Initiatives for Sustainable Development in collaboration with the University Institute of European Studies (IUSE) in Turin, Italy and the University of Piemonte Orientale, Novara, Italy which are both beneficiaries of the European Union Research Executive Agency IRSES Project “Liberalism in Between Europe And China” (LIBEAC) coordinated by Aix-Marseille University (CEPERC). This work has been realized in the framework of Workpackages 4, coordinated by University Institute of European Studies (IUSE) in Turin, Italy.